News | July 11, 2022
India’s first homegrown mRNA COVID-19 vaccine likely to have low market penetration, says GlobalData
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
Subscribe To Our Newsletter & Stay Updated
